Protopic, Elidel Need “Black Box” Warning On Cancer Risk, FDA Cmte. Says

FDA's Pediatric Advisory Committee is recommending a "black box" warning for Novartis' Elidel and Fujisawa's Protopic based on a carcinogenicity risk with the eczema treatments

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet